In a recent research note, the analysts at Jefferies make a big move by removing a top medical devices company from the firm's well-respected Franchise Picks list of stocks.
The relentless populist rhetoric has lowered the prices on some of the top pharmaceutical companies, and long-term growth and income investors have a chance to buy some great stocks on sale.
The top analyst upgrades, downgrades and initiations seen on Monday morning include AbbVie, Chevron, Home Depot, Nike, Qualcomm and VMware.
AbbVie reported mixed third-quarter financial results and a dividend hike before the markets opened on Friday.
Chris Lange Four companies in four very different sectors that all offer liquidity, a degree of safety and solid dividends that should continue to rise.
The October 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
The September 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest was mixed.
In a new research report from Jefferies, many of the outstanding companies in pharmaceuticals and biotech space show up among the stocks to buy.
Any of these three top pharmaceutical companies makes an outstanding addition to more conservative portfolios. They are also far less volatile and act better than biotechs if the market gets dicey.
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
In a recent research note, the analysts at Jefferies make a big move by adding a top technology company to the firm's well respected Franchise Picks list of stocks to Buy.
In a time when government wrangling about drug prices is more than commonplace, news of a biosimilar for the mega-blockbuster Humira being approved took the backseat to many other things.
Most Wall Street strategists agree that the way to play the fourth quarter and next year is with large cap stocks that pay and consistently increase their dividends.
